Skip to content

Alume Biosciences

6 viewers · 30d

Total raised

$9.0M

+$2.2M this year

6 filings since 2025 · latest SAFE filed

Cumulative raised
LAST ROUND
SAFE · $2.2M
ROUNDS
6
INVESTORS
46
FOUNDED
N/A
HQ
La Jolla, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

Alume Biosciences is a clinical-stage biotechnology company in La Jolla, California developing fluorescent imaging agents that make nerves visible to surgeons in real time during an operation. Its lead candidate, bevonescein (ALM-488), is a peptide-dye conjugate given intravenously about an hour before surgery that binds nerve tissue and fluoresces under specialized imaging, then clears through the kidneys within hours. The company was founded in 2017 by CEO Quyen Nguyen and the late Nobel laureate Roger Tsien, and is running bevonescein in Phase 3 trials with an FDA New Drug Application planned for 2026.

What sets it apart

A systemically administered nerve-specific fluorescent agent, rather than a device or dye that highlights tumors or vasculature, giving surgeons direct intraoperative visualization of nerves that are otherwise identified by anatomy and feel alone.

Funding history

6 rounds
SAFE+2Mar 24, 2026 · $50K min
Form D
+$110K$9.0M total
SAFE+2Mar 24, 2026 · $50K min
Form D/A
+$2.2M$9.0M total
EquityOct 30, 2025 · $25K min
Form D
+$3.1M$6.9M total
EquityOct 30, 2025 · $25K min
Form D/A
+$3.6M$6.9M total
EquityOct 30, 2025 · $25K min
Form D/A
+$6.0M$6.9M total
EquityOct 30, 2025 · $25K min
Form D/A
+$6.9M$6.9M total

Products

1 tracked

Bevonescein (ALM-488)

Surgical imaging agent

An investigational peptide-dye conjugate administered intravenously roughly 60 minutes before surgery that causes nerves to fluoresce, letting surgeons see and avoid them intraoperatively. It is in Phase 3 clinical trials, with a planned FDA New Drug Application in 2026.

  • Intravenous dose given approximately 60 minutes before the procedure
  • Peptide targets nerve tissue and makes it fluoresce for intraoperative visualization
  • Clears through the kidneys within hours after surgery
  • Currently in Phase 3 clinical trials

Links

WebsiteLinkedInSEC EDGAR filings